J
James N. Ingle
Researcher at Mayo Clinic
Publications - 403
Citations - 52917
James N. Ingle is an academic researcher from Mayo Clinic. The author has contributed to research in topics: Breast cancer & Tamoxifen. The author has an hindex of 82, co-authored 387 publications receiving 47883 citations. Previous affiliations of James N. Ingle include McMaster University & University of Rochester.
Papers
More filters
Journal ArticleDOI
Randomized trial of diethylstilbestrol vs. tamoxifen in postmenopausal women with metastatic breast cancer. An updated analysis.
TL;DR: Treatment with DES was more commonly associated with toxicity such as nausea, edema, vaginal bleeding, and cardiac problems, whereas hot flashes were commonly seen with TAM therapy, whereas the initial treatment with DES is associated with increased survival.
Journal ArticleDOI
Efficacy, Toxicity, and Quality of Life in Older Women With Early-Stage Breast Cancer Treated With Letrozole or Placebo After 5 Years of Tamoxifen: NCIC CTG Intergroup Trial MA.17
Hyman B. Muss,Dongsheng Tu,James N. Ingle,Silvana Martino,Nicholas J. Robert,Joseph L. Pater,Timothy J. Whelan,Michael Palmer,Martine Piccart,Lois E. Shepherd,Kathleen I. Pritchard,Zhi He,Paul E. Goss +12 more
TL;DR: Healthy patients age 70 years and older completing 5 years of tamoxifen should be considered for extended adjuvant therapy with letrozole.
Journal ArticleDOI
Efficacy of Letrozole Extended Adjuvant Therapy According to Estrogen Receptor and Progesterone Receptor Status of the Primary Tumor: National Cancer Institute of Canada Clinical Trials Group MA.17
Paul E. Goss,James N. Ingle,Silvana Martino,Nicholas J. Robert,Hyman B. Muss,Martine Piccart,Monica Castiglione,Dongsheng Tu,Lois E. Shepherd,Kathleen I. Pritchard,Robert B. Livingston,Nancy E. Davidson,Larry Norton,Edith A. Perez,Jeffrey S. Abrams,David Cameron,Michael Palmer,Joseph L. Pater +17 more
TL;DR: These results suggest greater benefit for letrozole in DFS, DDFS, and OS in patients with ER+/PgR+ tumors, implying greater activity of letroZole in tumors with a functional ER.
Journal ArticleDOI
The molecular etiology of breast cancer: evidence from biomarkers of risk.
Nilesh W. Gaikwad,Li Yang,Paola Muti,Jane L. Meza,Sandhya Pruthi,James N. Ingle,Eleanor G. Rogan,Ercole L. Cavalieri +7 more
TL;DR: The depurinating estrogen‐DNA adducts are possible biomarkers for early detection of breast cancer risk and response to preventive treatment.
Journal ArticleDOI
Two concurrent phase II trials of paclitaxel/carboplatin/trastuzumab (weekly or every-3-week schedule) as first-line therapy in women with HER2-overexpressing metastatic breast cancer: NCCTG study 983252.
Edith A. Perez,Vera J. Suman,Kendrith M. Rowland,James N. Ingle,Muhammad Salim,Charles L. Loprinzi,Patrick J. Flynn,James A. Mailliard,Carl G. Kardinal,James E. Krook,Abby R. Thrower,Daniel W. Visscher,Robert B. Jenkins +12 more
TL;DR: Every-3-week and weekly regimens of paclitaxel/carboplatin/trastuzumab are highly active in women with HER2-overexpressing MBC, and fewer patients developed severe neutropenia, leukopenia, or thrombocytopenia with the weekly schedule.